» Articles » PMID: 25287821

Four-week Prevalence of Mental Disorders in Patients with Cancer Across Major Tumor Entities

Abstract

Purpose: To provide the 4-week prevalence estimates of mental disorders in cancer populations.

Patients And Methods: We enrolled adult patients with cancer from in- and outpatient care facilities, using a proportional stratified random sample based on the nationwide cancer incidence in Germany. Patients who scored 9 or above on the Patient Health Questionnaire (PHQ-9) were administered to the standardized computer-assisted Composite International Diagnostic Interview for mental disorders adapted for cancer patients (CIDI-O). A random sample of those with a PHQ-9 score that was less than 9 were selected for a CIDI-O.

Results: A total of 5,889 patients were identified, which led to 4,020 participants (a 68.3% response rate); of those, 2,141 patients were interviewed. The 4-week total prevalence for any mental disorder was 31.8% (95% CI, 29.8% to 33.8%); this included any anxiety disorder (11.5%; 95% CI, 10.2% to 12.9%), any adjustment disorder (11.1%; 95% CI, 9.7% to 12.4%), any mood disorder (6.5%; 95% CI, 5.5% to 7.5%), any somatoform/conversion disorder (5.3%; 95% CI, 4.3% to 6.2%), nicotine dependence (4.5%; 95% CI, 3.6% to 5.4%), alcohol abuse/dependence (0.3%; 95% CI, 0.1% to 0.6%), any mental disorder resulting from general medical condition (2.3%; 95% CI, 1.7% to 2.9%), and any eating disorder (0%). The highest prevalence for any mental disorder was found in patients with breast cancer (41.6%; 95% CI, 36.8% to 46.4%), followed by patients with head and neck cancer (40.8%; 95% CI, 28.5% to 53.0%). The lowest prevalence was found in patients with pancreatic cancer (20.3%; 95% CI, 8.9% to 31.6%) and stomach/esophagus cancers (21.2%; 95% CI, 12.8% to 29.6%).

Conclusion: Our findings provide evidence for the strong need for psycho-oncological interventions.

Citing Articles

The impact of experiential avoidance on anxiety and depressive disorders in hematological cancer patients.

Weissflog G, Ernst J, Esser P, Platzbecker U, Vucinic V, Mehnert-Theuerkauf A J Behav Med. 2025; .

PMID: 39924603 DOI: 10.1007/s10865-025-00553-2.


Psychosocial distress, perceived need and utilization of psycho- social support services in patients in the early phase after the first cancer diagnosis.

Zingler H, Steinmann D, Ernst J, Goerling U, Hermann M, Hornemann B J Cancer Res Clin Oncol. 2025; 151(2):65.

PMID: 39912968 PMC: 11802609. DOI: 10.1007/s00432-025-06107-y.


Screening for anxiety in patients with cancer: Diagnostic accuracy of GAD-7 items considering lowered GAD-7 cut-offs.

Grapp M, Bugaj T, Terhoeven V, Friederich H, Maatouk I PLoS One. 2025; 20(1):e0316853.

PMID: 39808670 PMC: 11731751. DOI: 10.1371/journal.pone.0316853.


Course of Mental Disorders in Early Cancer Survivorship in Relation to Socioeconomic Status: A Multi-Center Prospective Longitudinal Study (LUPE).

Springer F, Goerling U, Zimmermann T, Ernst J, Engel C, Hermann M Psychooncology. 2025; 34(1):e70059.

PMID: 39780021 PMC: 11711303. DOI: 10.1002/pon.70059.


SarkoLife: quality of life in patients undergoing multimodal soft tissue sarcoma treatment.

Hoffmann S, Hoffmann T, Potkrajcic V, Deinzer C, Benzler K, Zender L World J Surg Oncol. 2025; 23(1):10.

PMID: 39773479 PMC: 11708100. DOI: 10.1186/s12957-024-03632-x.